Human cancer gene therapy with cytokine gene-modified cells

Expert Opinion on Biological Therapy

Volumn 4, Issue 10, 2004, Pages 1595-1607

  Wysocki, Piotr J ^a   Karczewska Dzionk, A ^a   Mackiewicz Wysocka, M ^a   Mackiewicz, A ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cytokines; Gene modified cancer vaccines; Human gene therapy

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7;

ANOREXIA; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER GENETICS; CANCER IMMUNOTHERAPY; CHILL; CHRONIC TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; FATIGUE; FEVER; FLU LIKE SYNDROME; GENE; GENE DELIVERY SYSTEM; GENE THERAPY; GENETICALLY MODIFIED CROP; HEADACHE; HUMAN; IL2 GENE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSTIMULATION; INTERFERON GENE; MALAISE; MYALGIA; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; VACCINE PRODUCTION; WEIGHT REDUCTION;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CELL TRANSPLANTATION; CLINICAL TRIALS; CYTOKINES; DEFECTIVE VIRUSES; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; INFECTION; INTERFERON TYPE II; INTERLEUKINS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, AUTOLOGOUS; TUMOR CELLS, CULTURED;

EID: 5644255720     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.10.1595     Document Type: Review

References (114)

1. JANEWAY CA JR: How the immune system works to protect the host from infection: a personal view. Proc. Natl. Acad. Sci. USA (2001) 98:7461-7468.
2. DIEFENBACH A, RAULET D: The inate immune response to tumors and its role in the induction of T-cell immunity. Immunol. Rev. (2002) 188:9-21.
3. KARRE K: NK cells, MHC class I molecules and the missing self. Scand. J. Immunol. (2002) 55:221-228.
4. ALBERT ML, PEARCE SF, FRANCISCO LM et al.: Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. (1998) 188:1359-1368.
5. BASU S, BINDER RJ, RAMALIGNAM T, SRIVASTAVA PK: CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70 and calreticulin. Immunity (2001) 14:303-313.
6. GALLUCCI S, LOLKEMA M, MATZINGER P: Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. (1999) 11:1249-1255.
7. GALLUCCI S, MATZINGER P: Danger signals: SOS to the immune system. Curr. Opin. Immunol. (2001) 13:114-119.
8. BANCHEREAU J, BRIERE F, CAUX C, DAVOUST J et al.: Immunobiology of dendritic cells. Annu. Rev. Immunol. (2000) 18:767-811.
9. BANCHEREAU J, STEINMAN RM: cells and the control of immunity. Nature (1998) 6673:245-252.
10. SMYTH MJ, CROWE NY, HAYAKAWA Y, TAKEDA K, YAGITA H, GODFREY DI: NKT cells - conductors of tumor immunity? Curr. Opin. Immunol. (2002) 14:165-171.
11. BRETSCHER P, COHN M: A theory of self-nonself discrimination. Science (1970) 169:1042-1049.
12. KIRKWOOD JM, STRAWDERMAN MH, ERNSTOFF MS et al.: Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: ECOG trial EST 1684. J. Clin. Oncol. (1996) 14:7-17.
13. KIRKWOOD JM, IBRAHIM JG, SONDAK VK et al.: High and low dose interferon alpha-2b in high risk melanoma. First analysis of intergroup trial E1690/S911C9190. J. Clin. Oncol. (2000) 18:2444-2458.
14. KIRKWOOD JM, IBRAHIM JG, SOSMAN JA et al.: High dose Interferon alfa 2b significantly prolongs relapse free survival compared with GM2-KLH/QS-21 vaccine in patients with resected stage IIB-II melanoma: results of intergroup trial E1694/S9512/C509081. J. Clin. Oncol. (2001) 19:2370-2380.
15. CASCINELLI N, BELLI F, MACKKIE RM et al.: Effect of long term adjuvant therapy with interferon alpha 2a in patients with regional node metastases from cutaneous melanoma. A randomized trial. Lancet (2001) 358:866-869.
16. CAMERON DA, CORNBLEET MC, MACKIE RM et al.: Adjuvant interferon alpha 2b in high risk melanoma - the Scottish Study. Br. J. Cancer (2001) 84:1146-1149.
17. GROB JJ, DRENO B, CHASTANG C et al.: Randomised trial of interferon α2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet (1998) 351:1905-1910.
18. KEFFORD RF: Adjuvant therapy of cutaneous melanoma: the interferon debate. Ann. Oncol. (2003) 14:358-365.
19. FISHER RI, ROSENBERG SA, FYFE G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. (2000) 6(Suppl. 1):S55-S57.
20. ROSENBERG SA, LOTZE MT, YANG JC et al.: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. (1993) 85:622-632.
21. ASSIER E, JULLIEN V, LEFORT J et al.: NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome. J. Immunol. (2004) 172:7661-7668.
22. FURTADO GC, CUROTTO DE LAFAILLE MA, KUTCHUKHIDZE N, LAFAILLE JJ: Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J. Exp. Med. (2002) 196:851-857.
23. SPITLER LE, GROSSBARD ML, ERNSTOFF MS et al.: Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. (2000) 18:1614-1621.
24. RINI BI, WEINBERG V, BOK R, SMALL EJ: Prostate-specific antigen kinetics as a measure of the biological effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J. Clin. Oncol. (2003) 21:99-105.
25. ANDERSON PM, MARKOVIC SN, SLOAN JA et al.: Aerosol granulocyte-macrophage colony-stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin. Cancer Res. (1999) 5:2316-2323.
26. COHEN J: IL-12 deaths: explanation and a puzzle. Science (1995) 270:908.
27. LEONARD JP, SHERMAN ML, FISHER GL et al.: Effects of single-dose interleukin-qw exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 90:2541-2548.
28. SELBY P, HOBBS S, VINER C et al.: Tumour necrosis factor in man: clinical and biological observations. Br. J. Cancer (1987) 56:803-808.
29. FEINBERG B, KURZROCK R, TALPAZ M, BLICK M, SAKS S, GUTTERMAN JU: A Phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J. Clin. Oncol. (1988) 6:1328-1334.
30. LIENARD D, EWALENKO P, DELMOTTE JJ, RENARD N, LEJEUNE FJ: High-dose recombinant tumor necrosis factor α in combination with interferon γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. (1992) 10:52-60.
31. DRANOFF G, JAFFE E, LAZENBY A et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA (1993) 90:3539-3543.
32. MACH N, GILLESSEN S, WILSON SB, SHEEHAN C, MIHM M, DRANOFF G: Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. (2000) 60:3239-3246.
33. ROSENBERG SA, AEBERSOLD P, CORNETTA K et al.: Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumour-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. (1990) 323:570-578.
34. ROTHER RP, SQUINTO SP, MASON JM, ROLINS SA: Protection of retroviral vector particles in human blood through complement inhibition. Hum. Gene Ther. (1995) 6:429-435.
35. CHRIST M, LUSKY M, STOECKEL F et al.: Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol. Lett. (1997) 57:19-25.
36. GORZIGLIA M, KADAN MJ, YEI S et al.: Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. (1996) 70:4173-4178.
37. MORSY MA, GU M, MOTZEL S et al.: An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. USA (1998) 95:7866-7871.
38. TRONO D: Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther. (2000) 7:20-23.
39. YANG S, DELGADO R, KING SR et al.: Generation of retroviral vector for clinical studies using transient transfection. Hum. Gene Ther. (1999) 10:123-132.
40. WYSOCKI PJ, KOWALCZYK DW, IZYCKI D, GRABARCZYK P, KWIAS Z, MACKIEWICZ A: IL-6 and GM-CSF in tumor rejection model of renal cell cancer. Adv. Exp. Med. Biol. (2000) 495:393-397.
41. REILLY R, MACHIELS J-P, EMENS L et al.: The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. (2001) 61:880-883.
42. KAWANO T, CUI J, KOEZUKA Y et al.: Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Science (1997) 278:1626-1629.
43. GILLESSEN S, NAUMOV YN, NIEUWENHUIS EE et al.: CD1d-restricted T cells tegulate dendritic cell function and antitumor immunity in a gran ulocyte-macrophage colony-stimulating factor-dependent fashion. Proc. Natl. Acad. Sci. USA (2003) 100:8874-8879.
44. DONG Z, YONEDA J, KUMAR R, FIDLER IJ: Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor. J. Exp. Med. (1998) 188:755-763.
45. SOIFFER R, LYNCH T, MIHM M et al.: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (1998) 95:13141-13146.
46. SOIFFER R, HODI SF, HALUSKA F et al.: Vaccination with irradiated, autologus melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol. (2003) 21:3343-3350.
47. NEMUNAITIS J, STERMAN D, JABLONS D et al.: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl. Cancer Inst. (2004) 96:326-331.
48. SALGIA R, LYNCH T, SKARIN A et al.: Vaccination with irradiated autologus tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. (2003) 21:624-630.
49. JAFFEE EM, HRUBAN RH, BIEDRZYCKI B et al.: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a Phase I trial of safety and immune activation. J. Clin. Oncol. (2001) 19:145-156.
50. NELSON WG, SIMONS JW, MIKHAK B et al.: Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother. Pharmacol. (2000) 46:S67-S72.
51. SIMONS JW, JAFFEE EM, WEBER CE et al.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. (1997) 57:1537-1546.
52. SIMONS JW, MIKHAK B, CHANG JF et al.: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. (1999) 59:5160-5168.
53. BUBENIK J, VOITENOK NN, KIELER J et al.: Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumors in nu/nu mice. Immunol. Lett. (1988) 19:279-282.
54. BUBENIK J, ZEUTHEN J, BUBENIKOVA D, SIMOVA J, JANDLOVA T: Gene therapy of cancer: use of IL-2 gene transfer and kinetics of local T and NK cell subsets. Anticancer Res. (1993) 13:1457-1460.
55. RUSSELL SJ, ECCLES SA, FLEMMING CL, JOHNSON CA, COLLINS MK: Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int. J. Cancer (1991) 47:244-251.
56. VAN ELSAS A, AARNOUDSE C, MINNE CE et al.: Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccine. J. Immunother. (1997) 20:343-353.
57. IWANUMA Y, KATO K, YAGITA H, OKUMURA K: Induction of tumor-specific cytotoxic T lymphocytes and natural killer cells by tumor cells transfected with the interleukin-2 gene. Cancer Immunol. Immunother. (1995) 40:17-23.
58. GANSBACHER B, ZIER K, DANIELS B, CRONIN K, BANNERJI R, GILBOA E: Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. (1990) 172:1217-1224.
59. FEARON ER, PARDOLL DM, ITAYA T et al.: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 60:397-403.
60. TRUDEL S, LI Z, DODGSON C et al.: Adenovector engineered interleukin-2 expressin autologus plasma cell vaccination after high-dose chemotherapy for multiple myeloma - a Phase I study. Leukemia (2001) 15:846-854.
61. HAIGHT AE, BOWMAN LC, NG CY, VANIN EF, DAVIDOFF AM: Humoral response to vaccination with interleukin-2-expressing allogeneic neuroblastoma cells after primary therapy. Med. Pediatr. Oncol. (2000) 35:712-715.
62. SOBOL RE, FAKHRAI H, SHAWLER D et al.: Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. (1995) 2:164-167.
63. PALMER K, MOORE J, EVERARD M et al.: Gene therapy with autologus, interleukin-2-secreting tumor cells in patients with malignant melanoma. Hum. Gene Ther. (1999) 10:1261-1268.
64. SCHREIBER S, KAMPGEN E, WAGNER E et al.: Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a Phase I study. Hum. Gene Ther. (1999) 10:983-993.
65. OSANTO S, SCHIPHORST PP, WEIJL NI et al.: Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum. Gene Ther. (2000) 11:739-750.
66. LAW TM, MOTZER RJ, MAZUMDAR M et al.: Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer (1995) 76:824-832.
67. HAWKINS MJ, ATKINS MB, DUTCHER JP et al.: A Phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma. J. Immunother. (1994) 15:74-78.
68. SCHMIDT-WOLF IG, FINKE S, TROJANECK B et al.: Phase I clinical study applying autologus immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br. J. Cancer (1999) 81:1009-1016.
69. JANTSCHEFF P, HERRMANN R, SPAGNOLI G et al.: Gene therapy with cytokine-transfected xenogeneic cells (Vero-IL-2) in patients with metastatic solid tumors: mechanism(s) of elimination of the transgene-carrying cells. Cancer Immunol. Immunother. (1999) 48:321-330.
70. TARTOUR E, MEHTALI M, SASTRE-GARAU X et al.: Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. Br. J. Cancer (2000) 83:1454-1461.
71. GANSBACHER B, BANNERJI R, DANIELS B, ZIER K, CRONIN K, GILBOA E: Retroviral vector mediated gamma Interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. (1990) 50:7820-7825.
72. DAR M, ABDEL-WAHAB Z, VERVAERT C, DARROW T, BARBER J, SEIGLER HF: Transduction with the murine interferon gamma gene leads to long-term immunological memoty. Ann. Surg. Oncol. (1996) 3:247-254.
73. BARON S, COPPENHAVER DH, DIANZANI F et al.: Introduction to the interferon system. In: Interferon: Principles and Medical Applications. Baron S, Coppenhaver DH, Dianzani F (Eds), Galveston, University of Texas, TX, USA (1992):1-15.
74. OGASARAWA M, ROSENBERG S: Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transducrion of melanoma cells with gamma IFN genes. Cancer Res. (1993) 53:3561-3568.
75. ABDEL-WAHAB Z, OSANTO S, DARROW TL et al.: Transducrion of human melanoma cells with the gamma interferon gene enhances cellular immunity. Cancer Gene Ther. (1994) 1:171-179.
76. QIN Z, BLANKENSTEIN T: CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity (2000) 12:677-686.
77. VALENTE G, OZMEN L, NOVELLI F et al.: Distribution of interferon-gamma receptor in human tissues. Eur. J. Immunol. (1992) 22:2403-2412.
78. SGADARI C, ANGIOLILLO AL, CHERNEY BW et al.: Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc. Natl. Acad. Sci. USA (1996) 93:13791-13796.
79. SGADARI C, FARBER JM, ANGIOLILLO AL et al.: Mig, the monokine induced by interferon-gamma promotes rumor necrosis in vivo. Blood (1997) 89:2635-2643.
80. KOWALCZYK DW, WLAZLO AP, GILES-DAVIS W, KAMMER AR, MUKHOPADHYAY S, ERTL HC: Vaccine-induced CDS+ T cells eliminate tumors by a two-staged attack. Cancer Gene Ther. (2003) 10:878-888.
81. ABDEL-WAHAB Z, WELTZ C, HESTER D et al.: A Phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells. Cancer (1997) 80:401-412.
82. GOLUMBEK PT, LAZENBY AJ, LEVITSKY HI et al.: Treatment of established renal cancer by tumor cells engineered to secrete inteleukin-4. Science (1991) 254:713-716.
83. TEPPER RI, COFFMAN RL, LEDER P: An eosinophil-dependent mechanism for the anti-tumor effect of interleukin-4. Science (1992) 257:548-551.
84. HOCK H, DORSCH M, KUNZENDORF U, QIN Z, DIAMANTSTEIN T, BLANKENSTEIN T: Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, inteleukin-4, interleukin-7, tumor necrosis factor, or interferon gamma. Proc. Natl. Acad. Sci. USA (1993) 90:2774-2778.
85. PERICLE F, GIOVARELLI M, COLOMBO MP et al.: An efficient Th2-type memory follows CDS+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J. Immunol. (1994) 153:5659-5673.
86. SALLUSTO F, LANZAVECCHIA A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte-macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor α. J. Exp. Med. (1994) 179:1109-1118.
87. ARIENTI F, BELLI F, NAPOLITANO F et al.: Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. (1999) 10:2907-2916.
88. BELLI F, MASCHERONI L, GALLINO G et al.: Active immunization of metastatic melanoma patients with IL-2 or IL-4 gene transfected, allogeneic melanoma cells. Adv. Exp. Med. Biol. (1998) 451:543-545.
89. MAIO M, FONSATTI E, LAMAJ E et al.: Vaccination of stage IV patients with allogeneis IL-4 or IL-2-gene transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol. Immunother. (2002) 51:9-14.
90. MILLER A, MCBRIDE W, DUBINETT S et al.: Transduction of human melanoma cell lines with human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunologic properties with interleukin-2. Blood (1993) 18:3686-3694.
91. MURPHY W, BACK T, CONLON K et al.: Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. J. Clin. Invest. (1993) 92:1918-1924.
92. FINKE S, TROJANECK B, MOLLER P et al.: Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the interlukin-7 gene to autologous and allogeneic immunologic effector cells. Cancer Gene Ther. (1997) 4:260-268.
93. CARSANA M, TRAGNI G, NICOLINI G et al.: Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine. Cancer Gene Ther. (2002) 9:243-253.
94. WITTIG B, MARTEN A, DORBIC T et al.: Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical Phase I/II trial. Hum. Gene Ther. (2001) 12:267-278.
95. RAKHMILEVICH AL, JANSSEN K, TURNER J, CULP J, YANG NS: Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of IL-12 Hum. Gene Ther. (1997) 8:1303-1311.
96. ZITVOGEL L, TAHARA H, ROBBINS PD et al.: Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J. Immunol. (1995) 155:1393-1403.
97. RAKHMILEVICH AL, TIMMINS JG, JANSSEN K, POHLMANN EL, SHEEHY MJ, YANG NS: Gene gun-mediated IL-12 gene therapy induces antitumour effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J. Immunother. (1999) 22:135-144.
98. LASEK W, BASAK G, SWITAJ T et al.: Complete tumour regression induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice. Cancer Immunol. Immunother. (2004) 53:363-372.
99. SWITAJ T, JALILI A, JAKUBOWSKA AB et al.: CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clin. Cancer Res. (2004) 10:4165-4175.
100. NAUME B, GATELY M, ESPEVIK T: A comparative study of IL-12 (cytotoxic lymphocyte maturation factor) IL-2, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J. Immunol. (1992) 148:2429-2436.
101. SUN Y, JURGOVSKY K, MOLLER P et al.: Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical Phase I study. Gene Ther. (1998) 5:481-490.
102. KANG WK, PARK C, YOON HL et al.: Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a Phase I study. Hum. Gene Ther. (2001) 12:671-684.
103. NEMUNAITIS J, BOHART C, FONG T et al.: Phase I trial of retro viral vector-mediated Interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma. Cancer Gene Ther. (1998) 5:292-300.
104. GILBOA E, LYERLY HK, VIEWEG J, SAITO S: Immunotherapy of cancer using cytokine gene-modified tumor vaccines. Semin. Cancer Biol. (1994) 5:409-417.
105. MACKIEWICZ A, WIZNEROWICZ M, ROEB E et al.: Interleukin-6-type cytokines and their receptors for gene therapy of melanoma. Ann. NY Acad. Sci. (1995) 762:361-373; discussion 373-374.
106. MACKIEWICZ A, WlZNEROWlCZ M, ROEB E et al.: Soluble interleukin 6 receptor is biologically active in vivo. Cytokine (1995) 7:142-149.
107. FISCHER M, GOLDSCHMITT J, PESCHEL C et al.: A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat. Biotechnol. (1997) 15:142-145.
108. OZBEK S, PETERS M, BREUHAHN K et al.: The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. Oncogene (2001) 20:972-979.
109. MACKIEWlCZ A, GORNY A, LACIAK M et al.: Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum. Gene Ther. (1995) 6:805-811.
110. WIZNEROWICZ M, FONG AZ, MACKIEWlCZ A, HAWLEY RG: Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: application to melanoma vaccine development. Gene Ther. (1997) 4:1061-1068.
111. NAWROCKI S, LACIAK M, IZYCKI D et al.: Humoral responses to melanoma vaccine, genetically modified with interleukin 6 and soluble interleukin 6 receptor. Adv. Exp. Med. Biol. (2001) 495:411-418.
112. OCHSENBEIN AF, KLENERMAN P, KARRER U et al.: Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA (1999) 96:2233-2238.
113. PEREZ-DIEZ A, SPIESS PJ, RESTIFO NP, MATZINGER P, MARINCOLA FM: Intensity of the vaccine-elicited immune response determines tumor clearance. J. Immunol. (2002) 168:338-347.
114. NEMUNAITIS J, BOHART C, FONG T et al.: Phase I trial of retroviral vector-mediated Interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma. Cancer Gene Ther. (1998) 5:292-300.